Christopher Trummer ^UDM

Christopher Trummer leads Celeris Therapeutics, an AI-first drug discovery company specializing in proximity-inducing compounds. The company focuses on diseases with high unmet medical needs, like Parkinson's and various cancers. Using its Celeris One platform, it combines structure-based geometric deep learning with an automated lab for rapid experimental data generation. Trummer's role is pivotal in steering the company's direction, including collaborations with other pharma and biotech companies, and developing an in-house drug pipeline.